Specific Marker of Sézary Cells Detection of Extracellular Vimentin as a SC5 mAb Represents a Unique Tool for the
暂无分享,去创建一个
[1] F. Fox,et al. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis. , 1997, Clinical and experimental immunology.
[2] H. Kerl,et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. , 1997, Blood.
[3] M. Nikolova,et al. Identification of Cell Surface Molecules Characterizing Human Cutaneous T-cell Lymphomas , 2002, Leukemia & lymphoma.
[4] R. Gascoyne,et al. Aberrant expression of T-plastin in Sezary cells. , 2003, Cancer research.
[5] M. Bagot,et al. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome. , 2004, The Journal of investigative dermatology.
[6] L. Old,et al. Cancer/testis (CT) antigens - a new link between gametogenesis and cancer. , 2001, Cancer immunity.
[7] D. Green,et al. Dicing with death: dissecting the components of the apoptosis machinery. , 1994, Trends in biochemical sciences.
[8] K. Bennett,et al. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. , 1996, Immunity.
[9] N. Dang,et al. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. , 2001, American journal of clinical pathology.
[10] S. Whittaker,et al. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. , 2003, Blood.
[11] A. Kotini,et al. Immunohistochemical expression of vimentin and secretory component antigens in endometrial hyperplasia and neoplasia. , 2002, European journal of gynaecological oncology.
[12] Y. Tokura,et al. CD7-positive Sézary syndrome with a Th1 cytokine profile. , 1996, Journal of the American Academy of Dermatology.
[13] M. Nikolova,et al. Killer cell immunoglobulin‐like receptor expression delineates in situ Sézary syndrome lymphocytes , 2003, Journal of Pathology.
[14] M. Polansky,et al. Variable CD7 expression on T cells in the leukemic phase of cutaneous T cell lymphoma (Sézary syndrome). , 2001, The Journal of investigative dermatology.
[15] R. Swerlick,et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. , 1992, The Journal of investigative dermatology.
[16] R. Willemze,et al. Aberrant Expression of the Tyrosine Kinase Receptor EphA4 and the Transcription Factor Twist in Sézary Syndrome Identified by Gene Expression Analysis , 2004, Cancer Research.
[17] I. N. Reid,et al. Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma , 2002, The Prostate.
[18] P. Nowell,et al. BCL2 and JUNB abnormalities in primary cutaneous lymphomas , 2004, The British journal of dermatology.
[19] R. Biassoni,et al. CD4(+) cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor. , 2001, Blood.
[20] D. Markovitz,et al. Vimentin is secreted by activated macrophages , 2003, Nature Cell Biology.
[21] R. Dummer,et al. Genotypic, phenotypic and functional analysis of CD4+CD7+ and CD4+CD7– T lymphocyte subsets in Sézary syndrome , 1999, Archives of Dermatological Research.
[22] D. Markovitz,et al. The Endothelial Cell-Specific Antibody PAL-E Identifies a Secreted Form of Vimentin in the Blood Vasculature , 2004, Molecular and Cellular Biology.
[23] M. Davison,et al. α-actinins and the DMD protein contain spectrin-like repeats , 1988, Cell.
[24] D. Schadendorf,et al. SEREX identification of new tumour‐associated antigens in cutaneous T‐cell lymphoma , 2004, The British journal of dermatology.
[25] M. Yacoub,et al. Antigenic heterogeneity of vascular endothelium. , 1992, The American journal of pathology.
[26] D. Ruiter,et al. Monoclonal antibody PAL-E specific for endothelium. , 1985, Laboratory investigation; a journal of technical methods and pathology.
[27] S. Meuer,et al. Human T lymphocyte activation induces tyrosine phosphorylation of α‐tubulin and its association with the SH2 domain of the p59fyn protein tyrosine kinase , 1995, European journal of immunology.
[28] A. Shevchenko,et al. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. , 1996, Analytical chemistry.
[29] Z. Li,et al. Cloning of a novel T-cell protein FYB that binds FYN and SH2-domain-containing leukocyte protein 76 and modulates interleukin 2 production. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[30] B. Dörken,et al. Identification of Apoptosis-associated Proteins in a Human Burkitt Lymphoma Cell Line , 1998, The Journal of Biological Chemistry.
[31] A. de Matteis,et al. The relevance of the CD4+ CD26– subset in the identification of circulating Sézary cells , 2001, The British journal of dermatology.
[32] M J O'Hare,et al. Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. , 2001, Cancer immunity.
[33] J. Jongstra,et al. A new lymphocyte-specific gene which encodes a putative Ca2+-binding protein is not expressed in transformed T lymphocyte lines. , 1988, Journal of immunology.
[34] P. Linsley,et al. Lymphocyte activation: T-cell regulation by CTLA-4 , 1996, Current Biology.
[35] M. Nikolova,et al. Increased expression of a novel early activation surface membrane receptor in cutaneous T cell lymphoma cells. , 2001, The Journal of investigative dermatology.